Description
Vinpocetine Forte Kanon Pharmacodynamics
It has vasodilator, antihypoxic and antiaggregation effects. Inhibits phosphodiesterase and increases cyclic adenosine monophosphate content in cells, which leads to a decrease of calcium in the cytoplasm of smooth muscle cells and relaxation of myofibrils. Dilates brain vessels, increases blood flow, mainly in ischemic areas, improves the supply of oxygen to the brain. Promotes glucose utilization and increases catecholamine levels in the central nervous system, stimulates metabolism of noradrenaline and serotonin in brain tissues. It reduces platelet aggregation and blood viscosity, increases red blood cell deformability and normalizes venous outflow against decreased cerebral vascular resistance. Systemic arterial pressure slightly decreases. In old age and old age, the sensitivity of cerebral vessels to the relaxing effect of vinpocetine increases, which is due to sensitization of the adenitate cyclic adenosine monophosphate system during aging.
Indications
Impaired cerebral circulation (including acute and reconstructive stages of ischemic stroke, reconstructive stage of hemorrhagic stroke, transient ischemic attack, encephalopathies, multi-infarct dementia).
Vascular diseases of the retina and/or choroid (due to arteriosclerosis, angiospasm, thrombosis); degenerative changes in the macula caused by atherosclerosis or angiospasm; secondary glaucoma (due to vascular occlusion).
Age-related vascular or toxic (drug-induced) hearing disorders, Meniere’s disease, vertigo of labyrinthine origin.
Vegetative manifestations of menopausal syndrome.
Contraindications
Hypersensitivity, marked cardiac arrhythmias, coronary heart disease (severe course), acute hemorrhagic stroke, pregnancy, lactation.
Dosage and administration
- Orally 1 tablet 3 times a day for 2 months. Before canceling the drug should gradually reduce the dosage. Possible repeated courses 2-3 times a year.
